About
Cure Today » Liver Cancer
by
2M ago
..read more
Visit website
All Videos
Cure Today » Liver Cancer
by
2M ago
..read more
Visit website
CURE Adventures
Cure Today » Liver Cancer
by
2M ago
..read more
Visit website
Blogs
Cure Today » Liver Cancer
by
2M ago
..read more
Visit website
Liver Cancer News From 2023
Cure Today » Liver Cancer
by
3M ago
In honor of Liver Cancer Awareness Month, CURE® highlighted some of the most impactful liver cancer developments from 2023 ..read more
Visit website
Poor Liver Function Can Cause Side Effects, Drug Discontinuation in HCC
Cure Today » Liver Cancer
by
3M ago
Patients with unresectable hepatocellular carcinoma and poor liver function were more likely to experience serious side effects leading to regorafenib treatment discontinuation, researchers have found ..read more
Visit website
Frontline Keytruda, Lenvima Betters Duration of Response in Advanced Liver Cancer
Cure Today » Liver Cancer
by
3M ago
Keytrida plus Lenvima improved survival and duration of response in patients with advanced hepatocellular carcinoma ..read more
Visit website
Rivoceranib-Airuika Combo Improves Survival in Liver Cancer Subset
Cure Today » Liver Cancer
by
9M ago
Rivoceranib plus Airuika demonstrates improvement for survival in patients with unresectable hepatocellular carcinoma, a subset of liver cancer ..read more
Visit website
First Patient Dosed With Novel CAR-M Cell Therapy Plus Keytruda for HER2-Overexpressing Cancer
Cure Today » Liver Cancer
by
10M ago
Treatment with a CAR-M cell therapy plus Keytruda is being assessed in a phase 1 study in patients with HER2-overexpressed tumors ..read more
Visit website
Imfinzi-Imjudo Combo Provides Survival Benefit Over 4 Years in Liver Cancer Subset
Cure Today » Liver Cancer
by
10M ago
Patients with unresectable hepatocellular carcinoma, a type of liver cancer, obtained a survival benefit over four years of follow-up with a treatment regimen of Imfinzi and Imjudo ..read more
Visit website

Follow Cure Today » Liver Cancer on FeedSpot

Continue with Google
Continue with Apple
OR